About ZEPATIER^®▼ (elbasvir and grazoprevir)

SIMPLE* POWER TO CURE** FOR CHRONIC HEPATITIS C^1-9

ZEPATIER is indicated for the treatment of chronic hepatitis C genotypes 1 and 4 infection in adults¹

ZEPATIER has the power to cure** in People Who Inject Drugs²
Find out more

ZEPATIER for all stages of Chronic Kidney Disease (CKD)³
Find out more

Drug-Drug Interactions and dosing simplicity of ZEPATIER*
Find out more

*“simple” is supported by the information held on the DDIs and dosing simplicity page

**Cure of HCV infection = sustained virologic response (SVR), the primary endpoint in all studies, was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) (=15 IU/ml) at 12 weeks after the cessation of treatment.^1,11

Related content

References

1. ZEPATIER summary of Product Characteristics.
2. Dore GL et al, Ann Int Med 2016;doi:10.7326/M16-0816 [Epub ahead of print]
3. Roth D et al. Lancet 2015:386:1537-1545.
4. Rockstroh JK et al. Lancet HIV 2015:2(8);319-327.
5. Zeuzem S et al. Ann Intern Med 2015; 163:1-13.
6. Forns X et al. J Hepatol 2015;63:564-572.
7. Kwo PY et al. C-EDGE TE EASL 2015.
8. Sperl J et al. Presented at EASL April 13-17 2016; Barcelona Spain: Abstract PS002.
9. Jacobson IM et al. Presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases; November 13-17 2015; Boston, MA.
10. Europena Association for the Study of the Liver. J Hepatol 2015;63:199-236.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ZEP-00052 | Date of Preparation: February 2019